Evolving Treatment Options in Lung Cancer
Saturday, January 13, 2018, Breakfast starts at 8:00 AM
Hilton Union Square Hotel
333 O'Farrell St
San Francisco, CA 94102

David R. Gandara, MD
Program Director

Matthew Gubens, MD, MS
University of California
San Francisco

Jonathan Riess, MD
UC Davis School of Medicine

Helen Shih, NP, MPH
UCSF Helen Diller Family Comprehensive Cancer Center

First Name: _________________________________________
Last Name: _________________________________________

( ) Physician ( ) Fellow ( ) Nurse ( ) PA ( ) Other

Institution: _________________________________________

Mailing Address: _____________________________________
City ______________ State ____ Zip Code _________

Phone Number: ______________________________________
Fax Number: _______________________________________

E-mail: ___________________________________________

**Agenda**

8:00-8:45AM: Breakfast and Registration

9:00-10:30AM: Keynote Speaker Lectures
- *Immunotherapy*, Dr. Gandara (UCD)
- *EGFR*, Dr. Reiss (UCD)
- *Oncogene Driven Cancers*, Dr. Gubens (UCSF)
- *Anticipation & Management of Immunotherapy Toxicities*, Ms. Shih (UCSF)

10:30-11:00AM: Break & Exhibits

11:00-12:30PM: “Molecular Tumor Board”
- **Moderator:** David Gandara
- **Panel:** Matthew Gubens, Jonathan Riess, Helen Shih

12:30-2:00PM: Lunch & Learn

**ONLY $25 TO REGISTER**

Register online at [www.cvent.com/d/ptqlwn](http://www.cvent.com/d/ptqlwn)
Call us at (561) 237-2845
Fax this form with the CC Form to (561) 771-1748
Email us at Megan@totalhealthconferencing.com
A CME INVITATION

A Master Lecture Series: Evolving Treatment Options in Lung Cancer
San Francisco, CA
Saturday, January 13, 2018
ONLY $25 TO REGISTER

8:00-8:45AM Breakfast and Registration
9:00-10:30AM Speaker Lectures
10:30-11:00AM Break & Exhibits
11:00-12:30PM Case Presentations and Panel Discussion
12:30-2:00PM Lunch and Learn

Conference Description
The lecture series will provide current, practical information on the management of lung cancer. We will discuss the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading experts will address critical topics in lung cancer, personalized therapy, and the latest clinical data impacting the treatment of lung cancer. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards with a lively and collaborative question-and-answer sessions will provide a unique opportunity for participants to participate with faculty as they share their viewpoints and personal practices on the clinical challenges and ongoing controversies in managing lung cancer patients. The audience will engage in case-based discussions and critical deliberations on the state of current knowledge, clinical findings, differential diagnoses and management plan options for their patients.

Learners Objectives
Upon completion of this activity, participants should be able to:

• Employ an understanding of personalized medicine to individualize the use of available drugs for lung cancer.
• Communicate the efficacy and safety of the drugs discussed in the case studies and other emerging treatments for lung cancer.
• Describe emerging data on the efficacy and safety of tumor immunotherapy lung cancer, and consider this information when counseling patients regarding clinical trial participation.
• Understand the emerging and standard diagnostic tests used to assist in planning therapy for lung cancer.
• Formulate management strategies for lung cancer, considering the contributory roles of local and systemic therapy.
• Recall the design of ongoing clinical trials evaluating novel investigational agents in lung cancer, and counsel appropriately selected patients about availability and participation.

Accreditation: The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The Medical Educator Consortium designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Disclosure Statement: The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.
Credit Card Authorization Form

DATE: _____ / _____ / ________  *AMOUNT: $__________________________

Event Date: _____ / _____ / ________  LOCATION: _________________________

*Use of credit cards will result in an additional 4% charge.

CARDHOLDER INFORMATION

Name: ____________________________________________

Company: ________________________________________

Billing Street Address: ______________________________

Street Address (cont.): ________________________________

City: ___________________________ State: ___________ Postal Code: ___________________________

Country: ___________________________ Email ________________________________

Direct Telephone: (_____)(_____)__________-

CREDIT CARD INFORMATION

Credit Card Type: □ MasterCard  □ Visa  □ American Express  □ Discover Card

Number: ______________________________________________

Expiration Month:_______  Expiration Year:___________  CVV # ________

Cardholder Signature X___________________________ Date___/___/___

Please Fax to:

Attention: Sarah Louden   Fax # (561) 771-1748

Total Health Information Services
20283 State Road 7, suite 400
Boca Raton, FL 33431